The definitive reference for TB-500 (Thymosin Beta-4 fragment) research — mechanism of action, dosage protocols, clinical trial data, legal status, and sourcing guide. All content is written for research purposes only.
Evidence quality analysis across 6 applications — tendon repair, cardiac protection, wound healing, and neuroregeneration.
Full molecular profile: amino acid sequence, mechanism of action, key signaling pathways, and research highlights.
The most researched peptide stack: synergy mechanisms, combined dosing protocols, and evidence quality.
Common questions about TB-500 from researchers
TB-500 is a synthetic peptide derived from Thymosin Beta-4, a naturally occurring protein found in virtually all human and animal cells. It is primarily studied for its role in tissue repair, wound healing, and angiogenesis. TB-500 acts by sequestering G-actin, which promotes cell migration and the formation of new blood vessels.
TB-500 is researched for tendon and ligament repair, cardiac muscle protection after injury, wound healing acceleration, neuroregeneration, and anti-inflammatory effects. The most studied application is cardiac repair, with RegeneRx Biopharmaceuticals having conducted Phase II/III trials for Thymosin Beta-4 in acute myocardial infarction.
TB-500 and BPC-157 are both studied for tissue repair but work through distinct mechanisms. TB-500 primarily acts through actin sequestration and angiogenesis, while BPC-157 works through VEGF upregulation and nitric oxide pathways. They are often stacked together because their mechanisms are complementary rather than redundant.
Research protocols typically use a loading phase of 2–2.5 mg twice weekly for 4–6 weeks, followed by a maintenance phase of 2–2.5 mg once weekly or biweekly. These figures are derived from animal studies and anecdotal research reports, not human clinical trial data.
TB-500 is a synthetic fragment of Thymosin Beta-4, specifically the actin-binding domain (amino acids 17–23 of the full 43-amino acid sequence). It is not identical to the full Thymosin Beta-4 molecule but shares its primary mechanism of action and most of its studied effects.
≥99% purity · Third-party COA on every batch · Ships same day
Evidence analysis of TB-500 (Thymosin Beta-4): actin-sequestering mechanism, wound healing, and anti-inflammatory research.
Evidence-based TB-500 dosage protocols: loading phase, maintenance dosing, and stacking with BPC-157.
Documented side effects of TB-500 from preclinical and clinical research — fatigue, nausea, and injection site reactions.
TB-500 legal status in the US, UK, and Australia — FDA classification, WADA ban, and research use regulations.
Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.